2018
DOI: 10.1021/acsbiomaterials.8b00300
|View full text |Cite
|
Sign up to set email alerts
|

Instructive Design of Triblock Peptide Amphiphiles for Structurally Complex Micelle Fabrication

Abstract: Hydrophobically driven self-assembly is a well-understood principle that has been shown to facilitate micelle formation. Although quite useful, the library of structures accessible is limited to only a few simplistic geometric configurations that are suboptimal for complex applications. It is believed that other physical phenomena like hydrogen bonding and electrostatic interactions can be exploited to complement hydrophobic interactions allowing for the design of structurally complex, aggregated micelles. To … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

6
62
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
4
3
1

Relationship

1
7

Authors

Journals

citations
Cited by 47 publications
(68 citation statements)
references
References 67 publications
6
62
0
Order By: Relevance
“…The combination of nucleic acid priming protein-enhanced immunoassay has made progress in the study of vaccines such as schistosomiasis, Japanese encephalitis, brucellosis, AIDS, tuberculosis 1-3 , malaria, etc., and its immune response is superior to a single nucleic acid vaccine or Protein vaccine [16 19]. Whether the N. meningitidis NMB0315 vaccine adopts the nucleic acid priming protein-enhanced combination immunization method is superior to the protein vaccine or nucleic acid vaccine alone [4][5][6][7][8][9][10][11][12] , has not been reported yet, and deserves further research and exploration.…”
Section: Figure 4 Antibody Titer Analysismentioning
confidence: 99%
See 1 more Smart Citation
“…The combination of nucleic acid priming protein-enhanced immunoassay has made progress in the study of vaccines such as schistosomiasis, Japanese encephalitis, brucellosis, AIDS, tuberculosis 1-3 , malaria, etc., and its immune response is superior to a single nucleic acid vaccine or Protein vaccine [16 19]. Whether the N. meningitidis NMB0315 vaccine adopts the nucleic acid priming protein-enhanced combination immunization method is superior to the protein vaccine or nucleic acid vaccine alone [4][5][6][7][8][9][10][11][12] , has not been reported yet, and deserves further research and exploration.…”
Section: Figure 4 Antibody Titer Analysismentioning
confidence: 99%
“…The CPS immunogenicity of the group B meningococcus serogroup B (MenB) is weak, and the structure is similar to the structure of N-acetylacetylneuraminic acid in human neural tissue, which may cause cross-reaction and trigger autoimmune diseases, limiting B. The successful development of the cerebral capsular polysaccharide vaccine [7,8]. Epidemic outbreaks are a global public health problem.…”
Section: Introductionmentioning
confidence: 99%
“…In order to obtain PLGA/CTAB microparticles with different CTAB contents, PLGA/CTAB microparticles were prepared by washing the precipitates with sterile ddH2O for 1, 2, 3, and 4 times after stirring overnight with magnetic stirrer [9], respectively, after adsorption with plasmid DNApCI-ORF5. The amount of DNA adsorbed and the sustained release were examined.…”
Section: Figure 1 Releasing Kinetic Of Plga Microparticlesmentioning
confidence: 99%
“…7, when immunized with the same dose of DNA, the neutralizing antibody of PLGA/CTAB-DNA microparticle immunization group was higher than that of naked DNA vaccine immunization group 8 weeks after the first dose (P<0. 05), and at low dose [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] .…”
Section: Figure 3 In Vitro Luciferase Expressionmentioning
confidence: 99%
“…The tumor antigen, which differentiates, activates, and matures under the action of GM-CSF, presents the decomposed antigen to T lymphocytes, and finally produces activated T lymphocytes capable of killing tumor cells [9]. GM-CSF gene-modified tumor vaccines have shown potential clinical value in experimental and clinical studies of melanoma [10], prostate cancer [11], lung cancer [12], and renal cancer [13] [1][2][3][4][5][6][7][8][9][10][11][12][13][14] . However, GM-CSF gene-modified liver cancer vaccine has not been reported 15 .…”
Section: Figure 3 Toxicity Assessmentmentioning
confidence: 99%